Actively Recruiting
Engineering Immune Organoids to Study Pediatric Cancer
Led by Gustave Roussy, Cancer Campus, Grand Paris · Updated on 2026-02-09
108
Participants Needed
2
Research Sites
259 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
CONDITIONS
Official Title
Engineering Immune Organoids to Study Pediatric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age at diagnosis 25 years or younger except for malignant gliomas and renal tumors with no upper age limit
- Medical suspicion or diagnosis of brain tumors
- Medical suspicion or diagnosis of renal tumors
- Medical suspicion or diagnosis of neuroblastoma
- Medical suspicion or diagnosis of sarcomas
- Patient or parent/guardian able to understand, sign, and date informed consent before study procedures
- Patient able and willing to comply with study visits and procedures
- Patient affiliated to or beneficiary of a social security system
You will not qualify if you...
- Any tumor histology not listed in the inclusion criteria
- Patient or parent/guardian unable to give informed consent
- Patients deprived of liberty by judicial or administrative decision
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Gustave Roussy
Villejuif, France, 94805
Actively Recruiting
2
Hopital Necker
Paris, Île-de-France Region, France, 75015
Actively Recruiting
Research Team
C
Claudia PASQUALINI, MD
CONTACT
J
Jérémy MIONE, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here